爱博医疗(688050) - 2024 Q1 - 季度财报

Financial Performance - The total operating revenue for Q1 2024 was 31,040.36 million RMB, a significant increase from 18,979.01 million RMB in Q1 2023, representing a growth of approximately 63.5%[15] - The company reported a net profit of 0 RMB for the period[17] - Net profit attributable to shareholders for Q1 2024 was CNY 10,290.34 million, up 31.26% compared to the same period last year[43] - The total profit amounted to CNY 11,513.67 million, up from CNY 8,688.28 million, reflecting a growth of 32.1%[64] - The net profit for the period was CNY 9,846.52 million, representing a 29.0% increase from CNY 7,643.69 million[64] - Basic earnings per share reached 0.30 yuan, in line with net profit growth[45] - Basic earnings per share were CNY 0.98, compared to CNY 0.75 in the previous period, marking a 30.7% increase[65] - The comprehensive income totalled CNY 9,846.33 million, up from CNY 7,643.69 million, reflecting strong overall performance[65] Operating Costs and Expenses - The total operating costs for Q1 2024 were 19,747.71 million RMB, compared to 10,568.60 million RMB in Q1 2023, indicating an increase of about 86.8%[15] - Research and development expenses totaled CNY 2,982.63 million, which is 19.00% higher than the previous year[43] - The proportion of R&D expenses to operating revenue decreased to 9.61%, down by 3.60 percentage points from the previous year[43] - Sales expenses increased significantly to CNY 4,752.69 million from CNY 2,783.68 million, reflecting higher marketing efforts[64] - Management expenses rose to CNY 3,621.23 million from CNY 2,186.13 million, indicating increased operational costs[64] - Financial expenses surged to CNY 316.34 million from CNY 47.91 million, primarily due to higher interest expenses[64] Cash Flow and Assets - The net cash flow from operating activities for Q1 2024 was CNY 5,395.48 million, reflecting a significant increase of 98.64% year-over-year[43] - The cash and cash equivalents at the end of Q1 2024 were CNY 36,787.84 million, down from CNY 53,665.83 million at the end of 2023[28] - The company’s cash and cash equivalents decreased to 29,306.36 million RMB from 37,776.95 million RMB[14] - The total assets at the end of the reporting period were 303,508.24 million RMB, slightly down from 306,178.66 million RMB at the end of the previous period[14] - Shareholders' equity attributable to the listed company increased by 4.02% to 221,515.45 million yuan compared to the previous year[58] Borrowings and Financial Obligations - The company’s long-term borrowings stood at 23,540.04 million RMB, down from 25,853.28 million RMB in the previous period[14] - The company’s short-term borrowings were 2,339.33 million RMB, a decrease from 2,554.78 million RMB[14] - The company reported a deferred income of 1,004.27 million yuan, reflecting its financial obligations[51] Shareholder Information - The number of common shareholders at the end of the reporting period was 10,997, with the top three shareholders holding a combined 24.32% of the shares[8] - The company repurchased 142,800 shares, accounting for 0.14% of the total share capital, with a total payment of approximately 20.04 million yuan[48] Other Financial Highlights - The company reported other income of CNY 480.99 million, a substantial increase from CNY 77.05 million, contributing positively to overall profitability[64] - Non-recurring gains and losses included government subsidies of 480.99 million yuan, contributing to the overall financial performance[44] - The company completed the construction and renovation of its medical device R&D center and production base in Beijing, which is now operational[11] - The company received approval for its preloaded non-spherical intraocular lenses from the National Medical Products Administration in China[26] - The company reported a significant increase in accounts receivable, which rose to CNY 27,640.76 million from CNY 21,281.84 million[28]